Variation in Patient Profiles and Outcomes in US and Non-US Subgroups of the Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) PHOENIX Trial | Zendy

Muthiah Vaduganathan | Zendy; Robert A. Harrington | Zendy; Gregg W. Stone | Zendy; Philippe Gabríel Steg | Zendy; C. Michael Gibson | Zendy; Christian W. Hamm | Zendy; Matthew J. Price | Zendy; Jayne Prats | Zendy; Efthymios Deliargyris | Zendy; Kenneth W. Mahaffey | Zendy; Harvey D. White | Zendy; Deepak L. Bhatt | Zendy

Open Access

Variation in Patient Profiles and Outcomes in US and Non-US Subgroups of the Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) PHOENIX Trial

Author(s) -

Muthiah Vaduganathan,

Robert A. Harrington,

Gregg W. Stone,

Philippe Gabríel Steg,

C. Michael Gibson,

Christian W. Hamm,

Matthew J. Price,

Jayne Prats,

Efthymios Deliargyris,

Kenneth W. Mahaffey,

Harvey D. White,

Deepak L. Bhatt

Publication year - 2016

Publication title -

circulation cardiovascular interventions

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.621

H-Index - 95

eISSN - 1941-7632

pISSN - 1941-7640

DOI - 10.1161/circinterventions.116.003612

Subject(s) - medicine , cangrelor , clopidogrel , percutaneous coronary intervention , odds ratio , confidence interval , cardiology , conventional pci , bivalirudin , clinical endpoint , aspirin , randomized controlled trial , myocardial infarction , p2y12

The Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) PHOENIX trial demonstrated superiority of cangrelor in reducing ischemic events at 48 hours in patients undergoing percutaneous coronary intervention compared with clopidogrel.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research